Key Facts on Vertex Pharmaceuticals
Vertex Pharmaceuticals (NASDAQ: VRTX) currently holds a dominant position in the cystic fibrosis (CF) market, responsible for marketing five approved therapies that address the genetic cause of the disease, affecting approximately 105,000 individuals worldwide. In contrast, SpaceX, despite its market impact, is projected to face increasing competition, particularly in its satellite internet sector.
The company’s recent performance highlights a significant financial disparity; Vertex reported adjusted earnings of $4.7 billion last year, while SpaceX incurred a net loss of $4.9 billion. Vertex also has promising developments in its pipeline, including a potential FDA approval for povetacicept for immunoglobulin A nephropathy by November 30, 2026, which could expand its market significantly.
Investors should note the valuation differences: SpaceX is trading at a forward price-to-sales multiple of 56.7, while Vertex’s is around 10. This suggests a more attractive risk-reward proposition for Vertex compared to investing in the highly speculative SpaceX.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
